Tag: equity

SINGAPORE, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ostium, a decentralized trading platform, has announced the launch of a new leveraged trading instrument: 0DTE perpetuals for equities. The instrument combines intraday expiry with perpetual structure, offering day traders up to 100x leverage on individual stocks during market hours — a structural innovation aimed at addressing the limitations of traditional options and CFDs.

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The Boards of Trustees/Directors of the PIMCO closed-end funds below (each, a “Fund” and, collectively, the “Funds”) have declared a monthly distribution for each Fund’s common shares as summarized below.

TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Lumine Group Inc. (“Lumine Group” or “the Company”) (TSXV:LMN) announces financial results for the three and six months ended June 30, 2025. All amounts referred to in this press release are in US dollars unless otherwise stated.

VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

HOUSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of July 31, 2025.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the “Grant Date”), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025.